Evidence map›Paper›PMID 28607028›Full record

ArticleAntimicrobial agents and chemotherapy2017

Chemoenzymatic Synthesis, Nanotization, and Anti-Aspergillus Activity of Optically Enriched Fluconazole Analogues.

Shashwat Malhotra, Seema Singh, Neha Rana, Shilpi Tomar, Priyanka Bhatnagar, Mohit Gupta, Suraj K Singh, Brajendra K Singh, Anil K Chhillar, Ashok K Prasad and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

Shashwat MalhotraBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Seema SinghCSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Neha RanaBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Shilpi TomarBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Priyanka BhatnagarCSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Mohit GuptaBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Suraj K SinghBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Brajendra K SinghBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Anil K ChhillarCentre for Biotechnology, Maharishi Dayanand University, Rohtak, Haryana, India.
Ashok K PrasadBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
Christophe LenSorbonne Universités, Université de Technologie de Compiègne, Ecole Supérieure de Chimie Organique et Minérale, Compiègne, France.
Pradeep KumarCSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Kailash C GuptaCSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Anjani J VarmaSchool of Chemical Sciences, Central University of Haryana, Mahendragarh, Haryana, India.
Ramesh C KuhadSchool of Chemical Sciences, Central University of Haryana, Mahendragarh, Haryana, India.
Gainda L SharmaCSIR-Institute of Genomics and Integrative Biology, Delhi, India drglsharma@hotmail.com virparmar@gmail.com RichardsN14@cardiff.ac.uk.
Virinder S ParmarBioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi, India drglsharma@hotmail.com virparmar@gmail.com RichardsN14@cardiff.ac.uk.
Nigel G J RichardsSchool of Chemistry, Cardiff University, Park Place, Cardiff, United Kingdom drglsharma@hotmail.com virparmar@gmail.com RichardsN14@cardiff.ac.uk.ORCID 0000-0002-0375-0881
University of Delhi · INInstitute of Genomics and Integrative Biology · INCentral University of Haryana · INCardiff University · GBMaharshi Dayanand University · INUniversité de Technologie de Compiègne · FRUniversity of Massachusetts Dartmouth · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in diagnostic and therapeutic methods in antifungal research, aspergillosis still remains a leading cause of morbidity and mortality. One strategy to address this problem is to enhance the activity spectrum of known antifungals, and we now report the first successful application of

Indexed as

A549 CellsAntifungal AgentsAspergillosisAspergillus fumigatusCell LineDisk Diffusion Antimicrobial TestsFluconazoleFungal ProteinsHumansLipaseNanoparticlesAntifungal AgentsFluconazoleFungal ProteinsLipaselipase B, Candida antarcticaantifungal agentsAspergilluschemoenzymatic synthesisfluconazole

Identifiers

PMID28607028
PMCPMC5527590
OpenAlexW2626084365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.